The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Association of a 2-weeks-on and 1-week-off schedule of sunitinib with decreased toxicity in metastatic renal cell carcinoma.
Yana George Najjar
No relevant relationships to disclose
Paul Elson
No relevant relationships to disclose
Laura S. Wood
Honoraria - AVEO; Bayer/Onyx; Novartis; Pfizer
Jorge A. Garcia
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer
Robert Dreicer
Consultant or Advisory Role - Novartis
Brian I. Rini
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer